Outer membrane vesicles from genetically engineered
 Salmonella enterica
 serovar Typhimurium presenting
 Helicobacter pylori
 antigens UreB and CagA induce protection against
 Helicobacter pylori
 infection in mice

Liu, Qiong; Shang, Yinpan; Shen, Lu; Yu, Xiaomin; Cao, Yanli; Zeng, Lingbing; Zhang, Hanchi; Rao, Zirong; Li, Yi; Tao, Ziwei; Liu, Zhili; Huang, Xiaotian

doi:10.1080/21505594.2024.2367783

Virulence

2024

DOI: 10.1080/21505594.2024.2367783

|View full text |Cite

Outer membrane vesicles from genetically engineered Salmonella enterica serovar Typhimurium presenting Helicobacter pylori antigens UreB and CagA induce protection against Helicobacter pylori infection in mice

Qiong Liu,

Yinpan Shang,

Lu Shen

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics

Savitri,

Fauzia,

Alfaray

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a bacterium known to be associated with a significant risk of gastric cancer in addition to chronic gastritis, peptic ulcer, and MALT lymphoma. Although only a small percentage of patients infected with H. pylori develop gastric cancer, Gastric cancer causes more than 750,000 deaths worldwide, with 90% of cases being caused by H. pylori. The eradication of this bacterium rests on multiple drug regimens as guided by various consensus. However, the efficacy of empirical therapy is decreasing due to antimicrobial resistance. In addition, biofilm formation complicates eradication. As the search for new antibiotics lags behind the bacterium’s ability to mutate, studies have been directed toward finding new anti-H. pylori agents while also optimizing current drug functions. Targeting biofilm, repurposing outer membrane vesicles that were initially a virulence factor of the bacteria, phage therapy, probiotics, and the construction of nanoparticles might be able to complement or even be alternatives for H. pylori treatment. This review aims to present reports on various compounds, either new or combined with current antibiotics, and their pathways to counteract H. pylori resistance.

show abstract

Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics

Savitri,

Fauzia,

Alfaray

et al. 2024

Microorganisms

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Outer membrane vesicles from genetically engineered Salmonella enterica serovar Typhimurium presenting Helicobacter pylori antigens UreB and CagA induce protection against Helicobacter pylori infection in mice

Cited by 1 publication

References 41 publications

Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics

Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics

Contact Info

Product

Resources

About